nivolumab + daratumumab + cyclophosphamide

Nivolumab + daratumumab + cyclophosphamide (NDc) is an investigational combination therapy evaluated for the treatment of relapsed or refractory multiple myeloma (RRMM). The regimen consists of nivolumab, a Programmed Death-1 (PD-1) checkpoint inhibitor; daratumumab, a monoclonal antibody targeting CD38; and low-dose oral cyclophosphamide, a small molecule alkylating agent. This combination was designed to enhance anti-tumor immunity by blocking the PD-1/PD-L1 pathway, depleting CD38-positive immunosuppressive cells, and providing cytotoxic chemotherapy. In the Phase 2 CheckMate 039 trial (NCT03184194), the addition of cyclophosphamide to the nivolumab-daratumumab doublet did not improve the objective response rate and was associated with increased hematologic toxicity and infections. Consequently, the triplet regimen was not selected for further clinical development, with researchers focusing on the nivolumab-daratumumab doublet instead.

Other names

NDcnivolumab, daratumumab, and cyclophosphamide